Matribhumi Samachar English
New York, New York–(Newsfile Corp. – April 15, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, …
Read More »Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder New York, New York–(Newsfile Corp. – April 8, 2025) – Psyence BioMed (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the signing of a Letter of Intent (LOI) with Southern Star …
Read More »